The T cell receptor repertoire has a potential for vast diversity. However, this diversity is limited by the fact that the majority of thymocytes die as the repertoire is shaped by positive and negative selection events during development . Such thymic selection affecting TCR VO gene segment usage has been demonstrated in the mouse. However, similar data has not been forthcoming in man, and little is known about the role of the TCR a chain in antigen/major histocompatibility complex (MHC) recognition in any species. Here, we used a monoclonal antibody recognizing the TCR Va12 .1 gene product to assess the expression of this gene in the peripheral blood of man. In most individuals tested, the percentage of cells expressing Va12 .1 was significantly higher in CD8 + T cells than in CD4+ T cells. That the Va gene product itself was responsible for this increased expression in CD8+ T cells was underscored by the lack of substantial skewing of V/3 usage in the Va12 .1-bearing T cells . Moreover, the skewed expression of Va111 was already present at birth, indicating that it was likely to be due to a developmental process rather than the result of exposure to environmental antigens. Based on the established role for CD8 in binding to class I MHC molecules, we suggest that increased expression of Va112 .1 on CD8+ T cells points to a role for TCR's using Va12 .1 in class I MHC/Ag recognition. These results indicate that Va gene usage in the peripheral blood of man is not random, and they support a role for Va as a participant in the self-MHC recognition process that shapes the TCR repertoire .
Summary
The T cell receptor repertoire has a potential for vast diversity. However, this diversity is limited by the fact that the majority of thymocytes die as the repertoire is shaped by positive and negative selection events during development . Such thymic selection affecting TCR VO gene segment usage has been demonstrated in the mouse. However, similar data has not been forthcoming in man, and little is known about the role of the TCR a chain in antigen/major histocompatibility complex (MHC) recognition in any species. Here, we used a monoclonal antibody recognizing the TCR Va12 .1 gene product to assess the expression of this gene in the peripheral blood of man. In most individuals tested, the percentage of cells expressing Va12 .1 was significantly higher in CD8 + T cells than in CD4+ T cells. That the Va gene product itself was responsible for this increased expression in CD8+ T cells was underscored by the lack of substantial skewing of V/3 usage in the Va12 .1-bearing T cells . Moreover, the skewed expression of Va111 was already present at birth, indicating that it was likely to be due to a developmental process rather than the result of exposure to environmental antigens. Based on the established role for CD8 in binding to class I MHC molecules, we suggest that increased expression of Va112 .1 on CD8+ T cells points to a role for TCR's using Va12 .1 in class I MHC/Ag recognition. These results indicate that Va gene usage in the peripheral blood of man is not random, and they support a role for Va as a participant in the self-MHC recognition process that shapes the TCR repertoire .
T cells play a central role in immunity through specific recognition of foreign peptides bound to self-MHC molecules . This recognition of antigen and self-MHC is carried out by clonotypic a(d T cell receptors, present on the surface of T lymphocytes in association with the CD3 complex (1) . TCR a and /3 chains are assembled by somatic recombination of discontinuous germline gene segments during T cell development . The generation of a diverse repertoire of human as TCRs is accomplished by the recombination of a single V gene segment (selected from a pool of approximately 100
Vas and 80 Vos) to an individual J gene segment (out of approximately 100 Jas and 13 JOs) . Template-independent nucleotide (N-segment) insertions at the junctions, Do usage, and the imprecise joining of the germline gene segments further increase TCR diversity (2, 3). However, in a given individual the potentially large repertoire of TCR structures may not actually be used by mature peripheral T cells . For instance, thymocytes bearing TCRs strongly autoreactive to self-MHC molecules are clonally deleted (negative selection) to achieve self-tolerance during thymic maturation (4, 5). In addition, lymphocytes bearing transgenic TCRs restricted to a particular MHC allele fail to develop fully in mice lacking the appropriate MHC molecule. These and other data led to the suggestion that a process of positive selection may also shape the peripheral TCR repertoire in mice and relate to the self-MHC restricted recognition of antigens by peripheral T lymphocytes (6) (7) (8) . With few exceptions, mature aO bearing T lymphocytes in the periphery are either CD8+ and restricted to class I MHC molecules, or are CD4+ and restricted to class II MHC molecules (9) .
Molecular modeling predicts that the V gene segment encoded CDR 1 and 2 may contact the MHC molecule, while the V (D(3)J junctional sequence encoded CDR3 may be oriented to interact predominantly with the foreign antigen peptide (3, 10) . However, most studies to date supporting the role of TCR segments in determining the fate of T cells during the process of thymic selection and in their subsequent function in cell-mediated immune responses are based largely on analyses of VO gene products (11, 12) . In contrast, little correlation between the expression of particular TCR a chains and MHC recognition or thymic selection has been reported. The few studies available to date implicate the TCR ce chain in foreign antigen specificity whereas little direct evidence has shown a role in MHC recognition .
Here, a Vcd11-specific mAb enabled us to analyze the expression of this gene segment in peripheral blood T cell subsets by flow cytometry. Most individuals expressed the Va12 .1 gene segment with significantly higher frequency (up to threefold) on CD8+ T cells in comparison with CD4' T cells. This phenomenon is likely to be mediated by a process acting on the Va12 .1 gene product itself, since the concomitant usage of Vii genes was heterogenous and similar in both CD4+ and CD8+ subsets of T cells. Moreover, the biased expression of Va1I1 on CD8+ T cells was present at birth, before antigenic challenge, suggesting that it may be the result of thymic selection events and not of foreign antigen-driven peripheral expansion.
Materials and Methods
Antibodies. The mAb 6136 was generated by injecting BALB/c mice at monthly intervals with TCR ag complexes isolated from the human T leukemia cell line HPB-MLT TCR complexes were partially purified by immunoprecipitation using anti-CD3 mAb adsorbed to Protein A bearing fixed Staphylococcus aureus bacteria (Pansorbin; Calbiochem Corp., San Diego, CA) using a protocol described previously (13) . Immune spleen cells were fused with P3X63Ag8.653 myeloma cells in the presence of polyethylene glycol 1500 (British Drug House, Carlplace, NY). The fused cells were then selected in the presence of hypoxanthine-aminopterinthymidine (Sigma Chemical Co., St . Louis, MO) at 101/well in 96-well plates . Supernatants from wells positive for growth were screened by immunoprecipitation on 115 1-labeled HPB-MLT cell lysates. One of the hybridomas that produced antibodies that specifically immunoprecipitated HPB-MLT TCRcomplex was selected and subdoned for additional study. The hybridoma product, mAb 6136, was identified as IgG1 by immunodiffusion analysis and is specific for Va111 encoded products (see Text).
MAb 3A2 was also generated against the HPB-MLT TCR agcomplex using the same protocol . It was shown to be specific for the S chain of HPB-MLT (V#5 .3) by immunoprecipitation experiments (see Fig. 2 B, lane 3) . In addition to immunofluorescence staining of HPB-MLT cell surface, approximately 1% of all T cells in PBL stain with mAb 3A2 (data not shown) . AntiTCR 0 framework antibody, OR, was also made in this laboratory (13) . MAb obtained from other sources include Leu-4 (anti-CD3) (14) , SPV T3b (anti-CD3) (15), OKT4 (anti-CD4), OKT8" (anti-CD8) (16), C305 (anti-V08) (17) , aFl (antiTCR a chain framework) (T Cell Sciences, Inc., Cambridge, MA), P3 (control) (18) and 187.1 (Rat anti-mouse K chain) (19) .
Immunofluorescence and Flow Cytometry. Flow cytometric analyses were performed using directly conjugated antibodies . Twocolor analyses on peripheral blood lymphocytes were carried out as described previously using a FACSCAN (Becton Dickinson and Co ., Mountainview, CA) (20) . Viable cells were analyzed by gating on the propidium iodide negative lymphocytes.
Radiolabeling and Immunoprecipitation. Cell surface radiolabeling of HPB-MLT cells was performed by using Na15 I and lactoperoxidase as previously described (21) . Biosynthetic labeling of TCR chains from HPB-MLT was carriedout as follows. Cells were washed and incubated at 5 x 106 cells/ml in methionine-and cysteinefree RPMI-1640 containing 10% dialyzed FCS, 2 mM glutamine and 20 mM HEPES at 37°C in 5% COa atmosphere . After 30
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Biased Va Expression on Human T Cells min, 0.5 mCi each of [3sS]-methionine and -cysteine were added and incubation continued for 4 h. Cells were pelleted and lysed in Tris-buffered saline (TBS, 50 mM Tris pH 7.5, 150 mM NaCl) containing 1% Triton X-100, 1 mM PMSF and S mM iodoacetamide . Cell lysates were pre-cleared twice using normal rabbit serum (NRS) and fixed S. aureus Cowan I (Pansorbin; CalbiochemBoehring Corp ., San Diego, CA). Specific immunoprecipitations were carried out using amounts of ascites determined to be optimal; 6136 (0 .1 Al), 3A2 (0 .4 wl), Len 4 (0 .1 i4l), OR (0 .25 p,l) or ctF1(0 .114). In each case 150 Al of mAb 187.1 (rat anti-mouse u) culture supernatant was added as a second antibody. After 60 min incubation at 4°C, 100 pl of 10% Protein-A sepharose CL4B (Pharmacia Fine Chemicals, Uppsala, Sweden) was added and incubated further for 30 min. Immune complexes were washed in 0.1% Triton X-100, resolved by SDS-PAGE and analyzed by autoradiography as described (22) . Derivation of 6136' T Cell Clones. PBMC were stimulated in vitro with 50 ng/ml of mAb 6136 in RPMI-1640 containing 2 mM glutamine, 20 mM HEPES, and 10% pooled human serum. Secondary stimulation was carried out using autologous PBMC (4,000 rads) and 50 ng/ml of 6136 antibody. After 3 wk in culture, the proportion of 6136+ cells in the CD3+ population rose from about 4% to 85%. Cells were cloned by plating at limiting dilutions in media containing IIL2 and a panel of 6136+ and 6136 -T cell clones was derived.
Southern Blot Hybridization . Genomic DNA was extracted from T cells by a standard technique (23) . DNA was digested with Bam HI restriction enzyme, size fractionated on 0.7% agarose gel and transferred to Hybond-N nylon membranes (Amersham Corp.) . DNA was cross-linked to the membranes by UVirradiation and hybridized with 32P-labeled probes. The Va12 .1 probe was an Eco RI Acc I (nucleotides -100 to +322) fragment of the TCRoe chain cDNA clone pGA5 (24) . Va DNA fragment was radiolabeled with [«-32p]-dGTP and -dCTP using random oligonucleotide primers and Klenow. Likewise, PCR products generated using the V(O and C/3-specific primers were size fractionated on 2% agarose gels, transferred to nylon filters, and hybridized with mixed 12 P-labeled C/31-(oligo #3CO) and C/32-specific (oligo #4CO) probes (see below) .
Statistical Analyses. To assess if the differences in expression of Va12 .1 in the CD4+ and CD8' T cell subsets were significant, two-sided Wilcoxon signed-ranked sum tests were used (25) .
hlymerase Chain Reaction. Total RNA was isolated from Ficollpurified mononuclear cells according to Chomczynski and Sacchi (26) . cDNA was synthesized at 42°C in 50 pl reactions using 0.5 Ncg oligo (dT) primer, 4 to 8 hg total RNA and 10 U of AMV reverse transcriptase (Promega Corp., Madison, WI). After 1 h, the reaction mixture was diluted to 100 pl, boiled and chilled, and centrifuged to remove insoluble material. PCR was performed in 25 pl reactions containing 1 A1 of cDNA (1/100), 1 mm MgCl2, 10 mM Tris pH 8.3, 1 mg/ml Gelatin, 5 pmole of each primer, 0.2 mM of each dNTP and 2 U of Taq-Polymerase (Thermus aquaticus DNA polymerase, Perkin-Elmer-Cetus Corp.) . Briefly, cDNA and primers were pre-mixed with MgClz/Tris/Gelatin buffer and heated at 95°C for 7 min. Other components were added, the reaction mix was overlain with mineral oil, and 25 to 30 cycles of PCR were carried out in a thermocycler (Perkin-Elmer-Cetus Corp .) at the following settings : 0.7 min at 95°C for denaturation, 1 min at 56°C for annealing, and 1 min at 72°C for chain extension. To ensure complete synthesis, the last cycle at 72°C was extended to 10 min.
Cloning in M13 and Sequencing Va111-specific (5' GGGG-TCGACTTGCCAGCCTGTTGAGGGCAG 3') and Ca-specific (5' GGGAAGCTTCTGGTACACGGCAGGGTCAGG 3') primers were used to generate PCR products using cDNA from 6136+ T cell clones. Restriction sites in the PCR primers were used to generate sticky ends for cloning. Appropriately sized DNA products were then isolated from low melting point (LMP) agarose gels (BRL, Gaithersburg, MD) and ligated to M13 plasmids for cloning and sequencing by the dideoxy chain termination method using the modified T7 polymerase (Sequenase; United States Biochemical Corp ., Cleveland, OH) (27) . The sequencing products were resolved on polyacrylamide gels and autoradiography was carried out according to standard methods.
Oligonucleodde Probes and Primers. VO-specific PCR products were generated using primers based on published sequences with some modifications (28, 29) . The oligonucleotide sequences for the VO-specific family members used in combination with the C/3 primers are listed below: V01-GGGGTCGACGCACAACAGT TCCCTGACTTGCAC(+) ; V02-GGGGTCGACTCATCAACC-ATGCAAGCCTGACCT(+); V#3-GGGGTCGACGTCTCTAG-AGAGAAGAAGGAGCGC(+); V/34-GGGGTCGACACATATGA GAGTGGATTTGTCATT(+); Vi35 .1-G000TCGACATACTTC-AGTGAGACACAGAGAAAC(+); V05.2/3-000GTCGACTTC-CCTAACTATAGCTCTGAGCTG(+) ; V06.1/2/3-GGGGTCG-ACAGGCCTGAGGGATCCGTCTC(+); V07-GGGGTCGACC-CTGAATGCCCCAACAGCTCTC(+) ; Va8-GGGGTCGACAT TTACTTTAACAACAACGTTCCG(+); V,B9-G000TCGACC-CTAAATCTCCAGACAAAGCTCAC(+) ; V#10-000GTCGAC-CTCCAAAAACTCATCCTGTACCTT(+ ); Vf11-000GTCGA-CTCAACAGTCTCCAGAATAAGGACG(+) ; V#12-000GTCG-ACAAAGGAGAAGTCTCAGAT(+); VQ13 .1-GGGGTCGACC-AAGGAGAAGTCCCCAATGGC(+); VS13 .2-GGGGTCGACG-GTGAGGGTACAACTGCCAAA(+); V014-000GTCGACGTC-TCTCGAAAAGAGAAGAGGAAT(+) ; V,B15-GGGGTCGACAG TGTCTCTCGACAGGCACAGGCT(+); V016-GGGGTCGAC-AAAGAGTCTAAACAGGATGAGTCC(+) ; V,817-000GTCGA-CCAGATAGTAAATGACTTTCAG(+) ; V018-GGGGTCGACG-ATGAGTCAGGAATGCCAAAGGAA(+) ; VS19-GGGGTCGA-CCAATGCCCCAAGAACGCACCCTGC(+); V020-GGGGT CGACAGCTCTGAGGTGCCCCAGAATCTC(+) ; #1CO-GGG-AAGCTTCTGATGGCTCAAACACAG(-); #2C#-GGGAAGC-TTACACCAGTGTGGCCTTTTGGGTG(-) ; #3CSTCGGGT GGGAACACGTTTTTC(-) ; #4COTCGGGTGGGAACACC-TTGTTC(-).
The 5' sense strand primers V011, V#14, V#15, V018 and V#19 were used in combination with the 3' anti-sense primer #2CO, while the rest of the V,8primers were used in combination with the primer #1Ca. This was to minimize PCR artifact (primer-dimer) formation due to possible 3`-end complementary bases shared between sense and anti-sense primers. Synthetic oligonucleotides were radiolabeled at the 5' termini with [y-'2P] using the enzyme bacteriophage T4 polynucleotide kinase. All of the PCR products were size fractionated, transferred and hybridized with internal region CO probes, #3C,8 and #4CO. VJ3specific PCR products were visualized by autoradiography and radioactivity was counted directly by using a blot analyzer (Betascope 603; Betagen Corp.) . (17) . lsotype matched mAb P3 was used as a negative control and mAb T3b (anti-CD3) was used as positive control. MAb 6136 was generated against the a(3 TCR complex isolated from HPB-MLT as described in Materials and Methods. Cell number scale is linear, fluorescence intensity scale is log. individuals (Fig. 1) . For comparison, mAb C305, specific for V08 encoded TCR products, also reacted with a few percent of peripheral blood T cells and the Jurkat cell line (which expresses VS8) but not with HPB-MLT cells (which express Va111 and V05.3) (Fig. 1) .
To determine the nature of the molecule recognized by mAb 6136, immunoprecipitations were performed on 1251_ labeled HPB-MLT cell lysates followed by SDS-PAGE and autoradiography. The mAb immunoprecipitated the TCR aft heterodimer (85 W) under nonreducing conditions (Fig . 2  A, lane 4) . This 85 kD heterodimer resolved into two species with Mr 46 kD (TCRct) and 39 kD (TCR,6) under reducing conditions (Fig. 2 A, lane 8) . For comparison, similar radiolabeled species were visualized after immunoprecipitations with TCR,B-specific mAb OF1 and CD3E-specific mAb Leu 4 (Fig. 2 A) . In both antiTCR and anti-CD3 immunoprecipitations, a variable degree of coimmunoprecipitation of the other components was noted.
To delineate the TCR chain specificity of mAb 6136, immunoprecipitations were carried out on HPB-MET cell lysates metabolically labeled with 35 [S]-methionine and -cysteine. Under these conditions a detectable fraction of the newly synthesized a and a TCR chains were still unpaired, such that mAb 6136 immunoprecipitated both a free a chain (migrating as a sharp band at 43 W), and the aio-heterodimers as fully glycosylated (80-85 kD) and partially glycosylated (70-75 W) structures (Fig . 2 B, lane 3) based on sizes reported earlier (30) . Immunoprecipitation with the anti-TCR a fi-amework antibody, ciF1, confirmed that the 43 kD species was the unpaired TCR a chain subunit (Fig . 2 B, lane 4) . The lanes 2 and 3, respectively) . In contrast, otF1(anti-framework) and 6136 antibodies (lanes 4 and S, respectively) immunoprecipitated the unpaired a chain from HPB-MLT cell lysates. While mAb ctP1 immunoprecipitated all of the glycosylated a chain species identified in HPB-MLT (13), mAb 6136 immunoprecipitated only one of these species . Note that mAb 6136 also recognized the TCR a/3 heterodimer as fully (80-85 kD) and partially (70-75 kD) glycosylated complexes (see text) .
other radiolabelled species (41-44 kD) in the c&l precipitation presumably corresponded to differentially glycosylated a chain species, as reported previously (13) . By comparison, other mAbs .that we generated including the anti-TCR (3 framework antibody, OR (lane 2), and antibody against the V6 product of HPB-MLT (3A2) (lane 3) both immunoprecipitated the unpaired /3-chain (38 kD) but not any of the free a chain species . Thus, mAb 6136 reacted with a determinant expressed on the TCR a chain .
To examine whether this determinant was encoded by Va, jot or a combination of both gene segments, 6136+ T cell clones derived from healthy individuals were analyzed . 642 Biased Va Expression on Human T Cells Southern blot analysis using the Va12.1-specific (pGA5) probe showed this Va gene to be rearranged in all the 6136+ T cell clones and the HPB-MLT leukemia cell line (Fig . 3 A) . The fact that the rearranged fragments were of different sizes in each cell line indicated that the Va12A gene segment which is part of a Va family having only one member (24, 31) , might be rearranging to several different Jot gene segments. This suggested that mAb 6136 recognized a Va rather than a Jot gene segment encoded determinant . Similarly, Northern blot analysis revealed expression of Va12 .1 transcripts in 6136+ T cell clones (data not shown) . These conclusions were confirmed by determining the nucleic acid sequences of the ot chain junctional regions of 6D6+ T cell clones HD5 .A and HD5 .B, and compared with the reported HPB.MLT sequence (24) . Each of the three 6D6 + T cell lines contained in-frame Vot12 .1 rearrangements to distinct Jot gene segments (Fig. 3 B) . These results demonstrated that mAb 6D6 specifically recognized the product encoded by the human V(r12 .1 gene segment . among the CD4' or CD8+ T cells by two-color staining (an example is shown in Fig. 4 A) , it was evident that most individuals had a non-random distribution of this gene segment among the two subsets (Fig . 4 B) . Analysis of the two phenotypic subsets separately showed that approximately 80% of individuals had a 1 . compared to CD4+ T cells (-x = 2 .7% ; range 1 .4% to 3 .6%) (p = 0.0044) (Fig. 4 B, Adult) . Only 20% of individuals used W12 .1 at similar frequency among CD4+ and CD8+ T cells. This result indicated that T cell receptor Va gene usage in man is nonrandom . This differential usage could have resulted either from developmental influences or from peripheral expansion as a consequence of foreign antigenic challenges. To distinguish these two possibilities, Va12 .1 expression was examined in newborn peripheral (umbilical cord) blood samples. Similar to the results seen in adult peripheral blood, significantly higher percentages of Va1I1 expression were seen in the CD8+ T cells of 10 newborns (p = 0.002) (Fig . 4 B, Newborn) . These data in the peripheral blood of newborns suggested the skewing was not likely to be the result of peripheral anti-64 4
Biased Va Expression on Human T Cells genic challenges and pointed instead to a developmental mechanism, possibly thymic selection . Analysis of V,8 Usage in Va12.1 + T Cells by Quantitative PCR . The preferential VcdI1 expression on CD8+ T cells was unexpected because essentially all known developmentally determined differences in TCR V gene usage are based on TCR V(3 expression and the presumed interaction of this gene segment with self-MHC or self-MHC antigen/superantigen complexes (32) . Therefore, it became important to examine TCR VJi usage in cells expressing the VcdI1 gene product . For this analysis, we used the PCR with VOspecific oligonucleotides known to detect up to 90% of all known human Vii genes. Such quantitative PCR techniques may not determine the precise percentage of T cells bearing the respective V genes (in-frame and out of frame sequences are not distinguished for example), but such approaches are known to be useful in approximating relative V gene usage (29) . Moreover, our own efforts to validate the procedure by mixing mRNA from T cell lines of known V gene usage revealed the expected proportions by PCR, at least for a sample of 3 V(3 genes analyzed (data not shown) . In Va12 .1+ (6136 selected) T cells, quantitative hybridization of VOspecific PCR products revealed that the majority of the V/3 genes were shared equally between the CD4+ and CD8+ subsets (Fig .  5 A and 5 B, upper panel) . No single V/3 gene dominated in its association with Va12 .1 . Importantly, the overall similarity in Va usage on Va12 .1 bearing CD4+ and CD8+ T cells suggested that skewed V(3 usage was not responsible for the increased level of Va111 expression on CD8 + T cells . In addition, most of the V# genes that were studied in the 6136 selected (Va111 + ) T cells were detected in similar amounts in CD4+ and CD8+ T cell subsets that had not been selected for Voa111 expression (Fig. 5 B, 6136 unselected; lower panel) . Thus V02, V07, V08 and V(313 which were the most prominently used VO genes in the Vcd1l selected T cells were also prominently used in C134' and CD8+ T cells not selected for Vcd1l expression (Fig. 5 B, compare patterns in upper and lower panels) . Moreover, the least frequently used Vss (V05, V)310, Va11, V316, V017, V018 and V#19) were also similar.
Some differences in VO expression among the subgroups were noted. For example, Vf7 and Va13 .1 which accounted for 11% and 10 .4% of the Vii gene segments in the Va12 .1 + /CD8+ subgroup were used at relatively lower levels in the Va12.1+/CD4+ subset where they made up 7 .5% and 5 .3%, respectively (Fig. 5 B, upper panel) . These usage levels together accounted for about a 9% difference between the two subsets . In fact, the sum of all differences in Vii frequency between the Vod2 .1+/CD8+ and Va12 .1 + /CD4 + T cells was only 16% . This total difference in V# usage was substantially less than the 60% that would have been required if skewed Vfl usage was to account for the 2 .5-fold increase in Vcd1l expression in this individual's CD8+ T cells .
While the above analysis examined V(3 expression on Vcd1l selected CD4+ versus CD8+ T cells, we also compared VO expression in Vcd1l selected and unselected T cell populations, we noted some evidence for preferential V(3 usage. For instance, in the CD4 + subset, V(615 was present on approximately 11% of the Va12 .1+ T cells compared with only approximately 3% of the T cell population not selected for Va12 .1 expression. In contrast, V013 .1 was less frequently used in Va111+ T cells (Fig. 5 B , compare upper and lower panels) . Nevertheless, even in these few examples where Va differences were seen between Vcd1l selected and unselected T cell populations, the differences were apparent to a nearly equal degree in both the CD4 + and CD8+ subsets, and therefore would seem not to be a likely explanation for the increased Va12 .1 expression on CD8+ T cells.
It is important to note that all of the V(3s tested are capable of association with Va12.1 and that no major Va product dominated in association with the Vcd1l gene product . A similar analysis of VO usage in newborn umbilical cord blood 64 5 DerSimonian et al.
also showed no dominant VO expression in association with Va12.1 and no significant difference in V# usage by the CD4+ and CD8+ subsets (data not shown). Thus, one cannot readily account for the significantly higher expression of Vcd1l on CD8+ T cells based on VO skewing.
Discussion
Ever since early functional studies pointed to the requirement for self-restriction in T cell recognition of foreign antigens, immunologists have tried to understand this phenomenon in molecular terms (33) . The binding of antigen peptides to MHC molecules has provided a molecular explanation for corecognition of Ag/MHC by the TCR (34-37), but the way in which different components of the TCR contribute to this Ag/MHC recognition has not been fully delineated . TCR gene sequences and hypothetical modeling based on immunoglobulin molecules suggest that the TCR V regions (especially those regions corresponding to CDR1 and CDR2) contact the MHC molecule, while the highly diverse V (D) J junctional region (corresponding to CDR3) contacts antigenic peptides bound to the MHC molecule (3, 10) . If these assumptions are correct, it should bepossible to correlate TCR germline gene segment usage with Ag/MHC recognition . In fact, several studies in mice have provided direct correlations between TCR V(3 gene segment usage and recognition of specific class II MHC/Ag complexes, mostly in association with the Mls antigens (38) (39) (40) (41) . However, the molecular basis of self-MHC recognition by the TCR is likely to be more complex than our current understanding which emphasizes only TCR VO gene products . The Va encoded regions also are likely to be important in Ag/MHC recognition as predicted by the molecular model .
With regard to the role of the TCR a chain, a few studies have correlated Va usage with foreign peptide or hapten recognition (42) (43) (44) (45) . Surprisingly, no molecular evidence has demonstrated a role for the Va gene segment in the recognition of MHC or Ag/MHC complex . This is in part because few Va-specific mAb have been available (46, 47) . Moreover in man, the greater number of germline gene segments, the more polymorphic MHC, and the inability to control genetic variation account for the fact that data measuring the actual TCR a or /3 repertoire and its relation to MHC-linked recognition and selection are currently very limited .
This study analyzes the cell surface expression of the human TCR Vcd1l gene product on CD4 + versus CD8+ T cells. Using a Va specific mAb, expression of the Va12 .1 gene segment was found to be significantly higher on CD8+ T cells in many of the individuals examined. Since CD8 + T cells in the periphery are class I MHC-restricted, the predominant expression of Vcd1l on CD8+ T cells makes it likely that the product encoded by this gene segment is used preferentially on class I MHC-restricted T cells in man . Based on our current understanding of MHC molecule expression, it is likely that the class I MHC molecule is expressed on the cell surface only in association with foreign or self-peptides (36) . Therefore, Vcd1l may be interacting directly with MHC and/or with a peptide bound to it. While a precise definition of what the Va is interacting with in this case is not known, the data are consistent with the likelihood that Va12 .1 is playing a role on CD8' T cells in recognition of class I MHC/Ag complex in vivo.
The increased expression of Va12 .1 in CD8+ T cells was apparent also in newborn samples, where environmental influences on the TCR repertoire via antigenic challenge would not yet have occurred . Thus it seems likely that the biased Va12 .1 usage results from developmental factors, rather than environmental ones. At present, we cannot distinguish thymic from extrathymic developmental influences, nor can we implicate a particular mechanism of thymic selection. In general (48), although not in every case (49), it has been suggested that negative selection of self-reactive thymocytes results in clonal deletion at the double positive (CD4+8+) stage of differentiation, resulting in deletion of the progenitors of both CD4+ and CD8+ mature T cells (50) . In contrast, positive selection has been suggested to result in the unequal distribution of the TCR repertoire between the CD4+ or CD8+ T cell subsets (7, 10, 51) . However, the actual mechanisms involved in thymocyte maturation are not well understood and selection may influence the T cell receptor repertoire at several intermediate stages during differentiation (52) . We find it attractive to hypothesize that positive selection in the thymus plays a role in the preferential Vca12 .1 expression in the CD8+ T cells by expanding a subset of MHC class Irestricted T cell precursors bearing Va12 .1 . Nevertheless, the data presented do not resolve the mechanism operating and further studies are needed to understand more fully the basis of biased Va12 expression .
In order to confirm that the Va12 .1 gene product was directly responsible for this nonrandom usage, it was important to consider the contribution made by the other TCR elements . Data from two unrelated individuals expressing typically higher Voc12 .1 levels in the CD8+ T cell subset showed no substantial differences in V(3 usage between CD4+ and CD8+ T cells . Furthermore, Ja gene usage in Vad2 .1 rearrangements was examined by nucleotide sequencing of 150 distinct inframe Va12.1 transcripts. This showed extensive diversity and no relative difference in Ja usage on Va12 .1+/CD4+ and Vct12 .1+/CD8+ cells (data not shown) . These results indicated that expression of the Va gene segment itself was the primary factor or element responsible for the relatively higher Va12.1 expression on CD8 + T cells, irrespective of concomitant jot and Va usage. In mice, major V(3 mediated thymocyte deletions occur as a result of Mls and class II MHC corecognition . Thus, in the murine system for some receptors the V/3 segment dominates in selection with the a chain being more passive. However in man, no striking V0 deletions have been reported, and we have found no major deletions among ten random donors. Thus, Mls-like/MHC class II based mechanisms of V0 deletion may participate to a smaller extent in shaping the receptor repertoire of mature human T cells. Our data on the analysis of one Va gene suggested that, at least in humans, some receptors may be selected during development with particular Va products dominating in the selection process.
